A European Multi-centre, Retrospective, Non-interventional Study of the Effectiveness of Tresiba (Insulin Degludec) After Switching Basal Insulin in a Population With Type 1 or Type 2 Diabetes Mellitus
Phase of Trial: Phase IV
Latest Information Update: 20 Mar 2018
At a glance
- Drugs Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EU-TREAT
- Sponsors Novo Nordisk
- 20 Mar 2018 Results presented at The 100th Annual Meeting of the Endocrine Society
- 06 Nov 2017 According to a Novo Nordisk media release, new analysis of real-world data was presented today at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR 2017) 20th Annual European Congress.
- 13 Jun 2017 Results (n=1717) evaluating the effectiveness of Insulin Degludec after switching from any other basal insulin in patients with type 1 diabetes mellitus, presented at the 77th Annual Scientific Sessions of the American Diabetes Association.